Death domain containing receptor 4 antibodies and methods

Details Death domain containing receptor 4 antibodies and methods Death domain containing receptor 4 antibodies and methods

2003-08-27

2008-11-18

Spector, Lorraine (Department: 1646)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S133100, C424S138100, C424S134100, C424S178100, C424S141100, C424S155100, C424S174100, C530S350000, C514S012200

Reexamination Certificate

active

07452538

ABSTRACT:
The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.

REFERENCES:
patent: 4002531 (1977-01-01), Royer
patent: 4179337 (1979-12-01), Davis et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5349053 (1994-09-01), Landolfi
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5763223 (1998-06-01), Wiley et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 6025158 (2000-02-01), Gonzalez et al.
patent: 6342363 (2002-01-01), Ni et al.
patent: 6433147 (2002-08-01), Ni et al.
patent: 6461823 (2002-10-01), Ni et al.
patent: 2003/0036168 (2003-02-01), Ni et al.
patent: 2003/0073187 (2003-04-01), Ni et al.
patent: 2003/0108516 (2003-06-01), Ni et al.
patent: 2045869 (1991-12-01), None
patent: 0 239 400 (1994-08-01), None
patent: 0 401 384 (1996-03-01), None
patent: 0 857 782 (1998-08-01), None
patent: WO 91/06570 (1991-05-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 95/06058 (1995-03-01), None
patent: WO 97/01633 (1997-01-01), None
patent: WO 98/30693 (1998-07-01), None
patent: WO 98/32856 (1998-07-01), None
patent: WO 98/41629 (1998-09-01), None
patent: WO 99/02653 (1999-01-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/37684 (1999-07-01), None
Base et al., A contribution to the treatment of non-seminomatous testicular tumours, Int. Unorology and Nephrology 16 (2):157-164, 1984.
Chinnaiyan et al., “Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95,”Science 24:990-992, American Association for the Advancement of Science (Nov. 1996).
Delgado et al., “The Uses and Properties of PEG-Linked Proteins,”Crit. Rev. Thera. Drug Carrier Sys. 9:249-304, Begell House (1992).
Goodman, J.W., “Immunogens & Antigens,” inBasic&Clinical Immunology, Stites et al., eds., Appleton & Lange, Norwalk, CT, pp. 20-27 (1988).
Huston et al., “Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins,”Methods in Enzymology 203:46-88, Academic Press (1991).
Morpurgo et al., “Covalent Modification of Mushroom Tyrosinase with Different Amphiphic Polymers for Pharmaceutical and Biocatalysis Applications,”Appl. Biochem. Biotechnol. 56:59-72, Humana Press (Jan. 1996).
Morrison, S.L. “Transfectomas Provide Novel Chimeric Antibodies,”Science 229:1202-1207, American Association for the Advancement of Science (1985).
Pan, G. et al., “The Receptor for the Cytotoxic Ligand Trail,”Science 276:111-113, American Association for Advancement of Science (Apr. 1997).
Roguska et al., “Humanization of murine monoclonal antibodies through variable domain resurfacing,”Proc. Natl. Acad. Sci. USA 91:969-973, National Academy of Science (1994).
Ruf et al., “Structure and Expression of the Gene Coding for the Alpha-Subunit of DNA-Dependent RNA Polymerase from the Chloroplast Genome of Zea Mays,”Nucl. Acids Res. 16:5741-5754, IRL Press (1988).
Wiley, S.R. et al., “Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis,”Immunity 3:673-682, Cell Press (1995).
Database, EMBL Nucleic Acid DB EBI, Accession No. AA100865, Hillier et al., (Oct. 1996).
GenBank Accession No. W65310, zd33e01.rl Soares fetal heart NbHH19WHomo sapienscDNA clone 342456 5′ similar to contains Alu repetitive element, NCBI National Library of Medicine Database, Bethesda, MD, USA, accessed Jan. 8, 1999, (Oct. 1996).
NCBI Entrez, GenBank Report, Accession No. AA150849, from Hillier, L., et al. (Dec. 1996).
NCBI Entrez, GenBank Report, Accession No. AA102745, from Hillier, L., et al. (Oct. 1996).
NCBI Entrez, GenBank Report, Accession No. AA102746, from Hillier, L., et al. (Oct. 1996).
NCBI Entrez, GenBank Report, Accession No. AA102383, from Hillier, L., et al. (Oct. 1996).
Chantry, D., “Tumour necrosis factor antagonists,”Emerging Drugs 4:5-13, Ashley Publications Ltd (1999).
Kim, K., et. al., “Molecular determinants of response to TRAIL combined with chemotherapy in killing of normal cancer cells,”Proceedings of the American Association for Cancer Research Annual Meeting 40:486, 90thAnnual Meeting of the American Association for Cancer Research (Apr. 1999).
Marsters, S.A., et. al., “Control of Apoptosis Signaling by Apo2 Ligand,”Recent Progress in Hormone Research 54:225-234, The Endocrine Society (1999).
International Search Report for International Application No. PCT/US 98/01464, European Patent Office, Netherlands, mailed on Jun. 17, 1998.
Supplementary Partial European Search Report for European Application No. EP 00 93 2061, European Patent Office, Netherlands, completed on Aug. 23, 2004.
Lerner, R.A., “Antibodies of Predetermined Specificity in Biology and Medicine,”Adv. Immunol. 36:1-44, Academic Press, Inc. (1984).
NCBI Entrez, GenBank Report, Accession No. AA639619, Strausberg, R., National Center for Biotechnology Information (1997).
Strader, C.D., et al., “Structural basis of β-adrenergic receptor function,”FASEB J. 3:1825-1832, Federation of American Societies for Experimental Biology (1989).
Walczak, H., et al., “TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL,”EMBO J. 16:5386-5397, Oxford University Press (1997).
Delgado, C., et al., “Quantitative analysis of polyethylene glycol (PEG) in PEG-modified proteins/cytokines by aqueous two-phase systems,”J. Biochem. Biophys. Methods 29:237-250, Elsevier Science B.V. (1994).
Dillman, R.O., “Monoclonal Antibodies for Treating Cancer,”Ann. Internal Med. 111:592-603, American College of Physicians (1989).
NCBI Genbank Accession No. U90875, Pan, G., et al., (Apr. 1997).
Pending U.S. Appl. No. 09/912,292, filed Jul. 26, 2001, Not Published: pp. 1-75 (pp. 1+2 partially redacted); portion of Table 2; and SEQ ID Nos. 7950 and 52011.
Delgi-Esposti, M.A., et al., “Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family,”J. Exp. Med.186:1165-1170, Rockefeller University Press (Oct. 1997).
Locksley, R.M., et al., “The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology,”Cell104:487-501, Cell Press (February 2001).
MacFarlane, M., “Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL,”J. Biol. Chem.272:25417-25420, American Society for Biochemistry and Molecular Biology (Oct. 1997).
Marsters, S.A., et al., “A novel receptor for Apo2L/TRAIL contains a truncated death domain,”Curr. Biol.7:1003-1006, Cell Press (Dec. 1997).
Pan, G., et al., “An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL,”Science277:815-818, American Association for the Advancement of Science (Aug. 1997).
Schneider, P., et al., “Characterization of two receptors for TRAIL,”FEBS Lett.416:329-334, Elsevier Science B.V. (Oct. 1997).
Screaton, G.R., et al., “TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL,”Curr. Biol.7:693-696, Cell Press (Sep. 1997).
Sheridan, J.P., et al., “Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors,”Science277:818-821. Ameri

Affiliated with

Also associated with

Rating

Death domain containing receptor 4 antibodies and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Death domain containing receptor 4 antibodies and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Death domain containing receptor 4 antibodies and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4048250